Ekso Bionics Holdings, Inc. (EKSO) Stock Price Down 32%
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s share price traded down 32% during trading on Tuesday . The stock traded as low as $1.61 and last traded at $2.02. 18,841,500 shares changed hands during mid-day trading, an increase of 2,975% from the average session volume of 612,670 shares. The stock had previously closed at $1.53.
Separately, Zacks Investment Research lowered shares of Ekso Bionics Holdings from a “hold” rating to a “sell” rating in a report on Monday.
The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.73 and a current ratio of 6.09.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. analysts predict that Ekso Bionics Holdings, Inc. will post -0.81 EPS for the current year.
In other Ekso Bionics Holdings news, insider Russ Angold sold 28,254 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $1.53, for a total value of $43,228.62. Following the sale, the insider now directly owns 250,678 shares of the company’s stock, valued at approximately $383,537.34. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have acquired 41,264 shares of company stock worth $48,255. 7.10% of the stock is owned by company insiders.
Large investors have recently made changes to their positions in the business. Carl Domino Inc increased its position in shares of Ekso Bionics Holdings by 74.7% in the 2nd quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after purchasing an additional 35,088 shares during the last quarter. Intellectus Partners LLC increased its position in shares of Ekso Bionics Holdings by 5.3% in the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after purchasing an additional 5,294 shares during the last quarter. National Planning Corp increased its position in shares of Ekso Bionics Holdings by 116.2% in the 2nd quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after purchasing an additional 126,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Ekso Bionics Holdings by 32.9% in the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares during the last quarter. 2.85% of the stock is currently owned by institutional investors.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.